Anavex Life Sciences (US:AVXL) Globenewswire·2025-09-02 11:30Core Viewpoint - Anavex Life Sciences Corp. is actively engaged in developing innovative treatments for various neurodegenerative and neurodevelopmental disorders, with a focus on presenting its advancements at the upcoming H.C. Wainwright 27th Annual Global Investment Conference [1][2]. Company Overview - Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to developing novel therapeutics for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, and Rett syndrome [3]. - The company's lead drug candidate, ANAVEX®2-73 (blarcamesine), has completed multiple clinical trials, including Phase 2a and Phase 2b/3 for Alzheimer's disease, and has shown potential in treating Parkinson's disease dementia and Rett syndrome [3]. - ANAVEX®2-73 is designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, with preclinical studies indicating its potential to halt or reverse Alzheimer's disease progression [3]. - ANAVEX®3-71, another promising drug candidate, targets SIGMAR1 and M1 muscarinic receptors, demonstrating disease-modifying activity against Alzheimer's disease in transgenic mice [3]. Upcoming Events - Christopher U. Missling, PhD, President and CEO of Anavex, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 1:00 p.m. ET [1][2].